Forest and Merz settle Namenda litigation
Generic versions of drug to enter market in 2015
Pharmaceutical developer Forest Laboratories of the US and partner Merz Pharmaceuticals of Germany have signed a patent litigation settlement agreement with 10 firms that were seeking to launch generic versions of Alzheimer’s drug Namenda (memantine hydrochloride) immediate release tablets.
Under the settlement agreements, the first generic versions of memantine will enter the market on 11 January 2015. This settlement agreement is subject to review by the US Federal Trade Commission.
Forest and Merz will provide licenses to Amneal, Watson, Dr. Reddy’s, Lupin, Mylan, Orchid, Sun, Teva, Upsher-Smith, and Wockhardt.